Constance Anderson, DO
Family Medicine · Ronceverte, WVNPI 1043237613
Payments from drug & device makers
Across 180 payments — averaging $16.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$591
- Lilly USA, LLC$429
- Amgen$263
- Amarin Pharma, Inc.$208
- Pfizer$178
- AbbVie$158
- plus $1K from 18 others
What the payments were for
- Food & beverage$2,911100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 39 | $591 |
| Lilly USA, LLC | 28 | $429 |
| Amgen | 17 | $263 |
| Amarin Pharma, Inc. | 12 | $208 |
| Pfizer | 10 | $178 |
| AbbVie(2 entities) | 8 | $158 |
| GSK | 10 | $155 |
| Abbott | 8 | $146 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $121 |
| Johnson & Johnson | 7 | $105 |
| E.r. Squibb & Sons, L.L.C. | 7 | $103 |
| Bayer | 5 | $77 |
| Novartis | 4 | $66 |
| Phathom Pharmaceuticals, Inc. | 3 | $49 |
| AstraZeneca | 3 | $48 |
| Biohaven Pharmaceuticals, Inc. | 2 | $44 |
| Sunovion Pharmaceuticals Inc. | 2 | $37 |
| Dexcom, Inc. | 2 | $31 |
| Esperion Therapeutics, Inc. | 2 | $29 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $18 |
| Baxter Healthcare | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Ultragenyx Pharmaceutical Inc. | 1 | $13 |
| Aroa Biosurgery Incorporated | 1 | $8 |
How this compares
$2,911 in reported general payments places this provider in the 80th percentile of 843 family medicine providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 2,283 | $605,658 |
| IngrezzaValbenazine Tosylate | 103 | $200,200 |
| OzempicSemaglutide | 170 | $180,511 |
| JanuviaSitagliptin Phosphate | 708 | $175,782 |
| TrulicityDulaglutide | 183 | $154,002 |
| AustedoDeutetrabenazine | 47 | $131,109 |
| JardianceEmpagliflozin | 409 | $112,218 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 107 | $87,603 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 219 | $65,184 |
| FarxigaDapagliflozin Propanediol | 238 | $62,980 |
| XareltoRivaroxaban | 121 | $40,103 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 75 | $38,698 |
| MyrbetriqMirabegron | 194 | $38,640 |
| Pantoprazole Sodium | 2,779 | $38,139 |
| NuplazidPimavanserin Tartrate | 20 | $37,630 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Premarin | $178 | $621,7332,321 claims |
| Novo NordiskOzempic, Rybelsus | $591 | $214,018209 claims |
| GSKTrelegy Ellipta, Arexvy, Breo Ellipta | $155 | $189,244392 claims |
| Lilly USA, LLCTrulicity | $429 | $154,002183 claims |
| AstraZenecaFarxiga, Brilinta, Breztri Aerosphere | $48 | $116,413550 claims |
| Sanofi-aventis U.S. LLCLantus, Multaq | $15 | $47,798392 claims |
| Johnson & JohnsonXarelto | $105 | $40,103121 claims |
| NovartisEntresto | $66 | $29,53282 claims |
| Otsuka Pharmaceutical Development & Commercialization, Inc.Tolvaptan | $18 | $27,12717 claims |
| AbbVieLinzess | $158 | $25,35140 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 843 family medicine providers in West Virginia.
Other family medicine in Ronceverte
- Wilbur SineMorgantown$179K
- Dorian WilliamsMorgantown$169K
- Julie DetempleSouth Charleston$129K
- Clemente DiazRichwood$127K
- John CornellHuntington$94K
- Mark CucuzzellaHarpers Ferry$59K
- Courtney PilkertonMorgantown$45K
- Isha WoofterClarksburg$27K
- Dominick WoofterClarksburg$27K
- Ryan RunyonPrinceton$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.